RY8 — Rongyu Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for Rongyu Pharmaceuticals, fiscal year end - March 31st, AUD millions except per share, conversion factor applied.
2015 March 31st | 2016 March 31st | 2017 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | AAS | AAS | AAS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 41.5 | 62.3 | 71.4 |
| Cost of Revenue | |||
| Gross Profit | 18 | 27.6 | 30.2 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 25.7 | 38.2 | 45.7 |
| Operating Profit | 15.8 | 24.1 | 25.8 |
| Net Income Before Taxes | 15.8 | 24.1 | 25.8 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 11.9 | 18.1 | 19.3 |
| Net Income Before Extraordinary Items | |||
| Net Income | 11.9 | 18.1 | 19.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 11.9 | 18.1 | 19.3 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0.03 | 0.045 | 0.048 |
| Dividends per Share |